Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inactivated sars-cov-2 vaccine + quadrivalent influenza vaccine (Sinovac Biotech Ltd.)
- Development stage
- Unknown
- Lead developer
- Sinovac Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This combination regimen involves the co-administration of Sinovac's CoronaVac (an inactivated SARS-CoV-2 vaccine) and an inactivated quadrivalent influenza vaccine (IIV4). CoronaVac is a whole-virion inactivated vaccine produced in Vero cells, designed to elicit neutralizing antibodies against the SARS-CoV-2 spike protein and other viral antigens. The IIV4 component contains inactivated antigens from four influenza strains, typically including two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). This combination was evaluated in a Phase IV clinical trial (NCT04801888) to assess the safety and immunogenicity of simultaneous administration, aiming to streamline vaccination schedules during overlapping viral seasons.
- Other names
- CoronaVac + IIV4SARS-CoV-2 inactivated vaccine + Quadrivalent Influenza Vaccine
02
Targets
SARS-CoV-2 spikeHA (Hemagglutinin)
Beyond the preview
Go deeper on inactivated sars-cov-2 vaccine + quadrivalent influenza vaccine (Sinovac Biotech Ltd.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inactivated sars-cov-2 vaccine + quadrivalent influenza vaccine (Sinovac Biotech Ltd.).